Immune cell senescence drives responsiveness to immunotherapy in melanoma

Abstract Background Immunotherapy has significantly improved cancer treatment. However, it is not effective in all cancer patients, rendering the need to further delineate the differences among responders and non-responders at the molecular and cellular level. Unresponsiveness to immunotherapy has b...

Descripció completa

Dades bibliogràfiques

Autors principals:	Pavlos Pantelis, Dimitrios Christos Tremoulis, Konstantinos Evangelou, Panagiotis Bakouros, Sophia Magkouta, Orestis A. Ntintas, Dimitris Veroutis, Giorgos Theocharous, Ioannis V. Kostopoulos, Dimitris-Foivos Thanos, Eftychia Chatziioannou, Ioanna A. Anastasiou, Nefeli Lagopati, Dimitrios Valakos, Dimitrios Skaltsas, Oltin Tiberiu Pop, Marie Therese Abdou, Sarantis Gagos, Dimitris Kletsas, Dimitris Thanos, Alexandros J. Stratigos, Martin Röcken, Lukas Flatz, George P. Chrousos, Dimitrios Vlachakis, Ourania E. Tsitsilonis, Russell Petty, Timokratis Karamitros, Vassilis G. Gorgoulis
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-12-01
Col·lecció:	Molecular Cancer
Matèries:	Immunotherapy Immune cell senescence Responders Non-responders Melanoma SeneVick
Accés en línia:	https://doi.org/10.1186/s12943-025-02517-1
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!